Prophylactic Treatment of Affective Disorders with Carbamazepine and Oxcarbazepine: An Open Clinical Trial

Greil, Waldemar; Krüger, Rejko; Rossnagl, G; Schertel, M.; Walther, Axel

doi:10.1007/978-1-4613-2363-1_77

Search citation statements

Order By: Relevance

Paper Sections

Select...

Psychiatric Uses Of Newer Anticonvulsants1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2001

2004

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A reduction in symptoms was noted with both agents; however, there was no decrease in the frequency of the manic episodes. 46 Tiagabine is FDA approved as an adjunct anticonvulsant for treatment of partial seizures. A review of the literature included an open-label trial of 8 patients in acute manic episodes treated with tiagabine.…”

Section: Psychiatric Uses Of Newer Anticonvulsantsmentioning

confidence: 99%

Psychiatric Uses of Newer Anticonvulsants

Berigan

2001

Prim. Care Companion CNS Disord.

View full text Add to dashboard Cite

Section: Psychiatric Uses Of Newer Anticonvulsantsmentioning

confidence: 99%

Psychiatric Uses of Newer Anticonvulsants

Berigan

2001

Prim. Care Companion CNS Disord.

View full text Add to dashboard Cite

Untitled

Pies

2002

Annals of Clinical Psychiatry

View full text Add to dashboard Cite

While the benefits of lithium in bipolar disorder are evident, its limitations as monotherapy are well recognized, particularly in bipolar depression. This has propelled trials of combined lithium-anticonvulsant therapy in many bipolar patients. The present review of the English-language literature examines both controlled and open studies of such combination therapy, including the risk of drug-drug interactions. Trials of lithium plus either carbamazepine or divalproex have generally produced favorable results, although increased rates of adverse effects may reduce treatment adherence. More recent reports suggest that lithium may be safely and effectively combined with lamotrigine, and perhaps with topiramate, although controlled studies are required. The combined use of lithium with newer, putative mood stabilizers, such as zonisamide or levetiracetam, cannot yet be recommended, but is an important area for future research. Provisional recommendations for combined treatment are provided.

show abstract

Oxcarbazepine: Efficacy, safety, and tolerability in the treatment of mania

Lande¹

2004

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

A twelve-week study examined the efficacy, safety, and tolerability of oxcarbazepine in the treatment of mania. Twenty male subjects, all of whom were stable on valproic acid, qualified for the study. The conversion from valproic acid to oxcarbazepine was completed over a three-week period. Scores from the BPRS, CGI and SAJEE-GI were collected and analyzed. The results of the study supported the efficacy, safety, and tolerability of oxcarbazepine for the treatment of mania. Another potential advantage of oxcarbazepine is a metabolic pathway that may reduce drug interactions. Qnt] Psych Can Pract 2004; 8: 37-40).

show abstract

Prophylactic Treatment of Affective Disorders with Carbamazepine and Oxcarbazepine: An Open Clinical Trial

Cited by 4 publications

References 4 publications

Psychiatric Uses of Newer Anticonvulsants

Psychiatric Uses of Newer Anticonvulsants

Untitled

Oxcarbazepine: Efficacy, safety, and tolerability in the treatment of mania

Contact Info

Product

Resources

About